Check out the latest news from Creative Diagnostics! We have just launched an amazing portfolio of Macrophage Migration Inhibitory Factor (MIF) reagents that are perfect for researchers. 
- (1888PressRelease) December 11, 2023 – Calling all researchers! Creative Diagnostics, the go-to manufacturer and supplier of antibodies, antigens, and assay kits, is thrilled to introduce our new portfolio of Macrophage Migration Inhibitory Factor (MIF) reagents. These tools are essential for researching MIF functions, disease pathogenesis, and potential treatment options. Our lineup includes Human MIF ELISA Kits, Human MIF Blocking Peptides, and various MIF Monoclonal/ Polyconal Antibodies.
MIF, a highly conserved 12.5 kDa secreted protein, is found in various cell types and tissues and plays a crucial role in the pathogenesis, invasion, and immune evasion of bacterial, parasitic, and viral infections. Researchers have made groundbreaking discoveries about the positive impact of blocking MIF action in mice when it comes to WNV lethality. This could open the door to new treatment strategies for WNV encephalitis.
The implications of MIF overexpression in numerous cancers cannot be overstated. Tumor aggressiveness and MIF expression have been found to be directly correlated. Furthermore, there is evidence of a positive correlation between intratumoral MIF and plasma MIF in hepatocellular carcinoma, indicating elevated levels of soluble MIF due to high expression of tumor-associated MIF.
As a pleiotropic inflammatory cytokine with upstream immunomodulatory effects, MIF is frequently linked to autoimmune diseases. Studies have shown that MIF gene deletion and anti-MIF therapy can improve disease activity in models of rheumatoid arthritis and systemic lupus erythematosus. Additionally, elevated levels of MIF protein have been observed in patients with neurological disorders such as schizophrenia, mild cognitive impairment, and Alzheimer’s disease.
Due to its diverse functions in the pathogenesis of inflammation, autoimmune diseases, and cancer cell proliferation and metastasis, MIF has emerged as a promising therapeutic drug target. Creative Diagnostics is proud to offer a range of MIF reagents to support researchers in their exploration of MIF function, disease pathogenesis, and potential therapeutic approaches.
Take, for example, our Anti-MIF monoclonal antibody (Catalog # CABT-13969MH), which can be used for WB, IHC, IP, sELISA, and ELISA. It’s raised against a full-length recombinant MIF and is a vital tool for studying cell-mediated immunity, immunomodulation, and inflammatory responses. Additionally, our MIF ELISA Kit (Catalog # DIA-XYA180) contains all the necessary components for quantitatively determining the concentration of natural or recombinant human MIF in any experimental sample.